Chiasma Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
12,849.60
40,160.40
148,754.00
92,984.00
66,939.00
41,662
Other Current Assets
438.40
311.30
2,331.00
2,110.00
1,768.00
2,237
Total Current Assets
13,288.00
40,471.70
151,085.00
95,094.00
68,707.00
62,187
Net Property, Plant & Equipment
1,056.20
615.20
676.00
683.00
193.00
111
Total Investments and Advances
-
-
1,300.00
-
-
-
Other Assets
314.10
311.70
47.00
979.00
983.00
958
Total Assets
14,658.30
41,398.70
153,108.00
96,756.00
69,883.00
63,256
ST Debt & Current Portion LT Debt
-
-
1,700.00
1,700.00
-
Accounts Payable
2,339.60
318.00
-
-
1,017.00
Income Tax Payable
100.50
-
-
-
-
Other Current Liabilities
12,024.90
4,000.30
4,814.00
6,700.00
5,728.00
Total Current Liabilities
14,465.10
4,318.30
6,514.00
8,400.00
6,745.00
Long-Term Debt
-
-
3,400.00
1,700.00
-
Provision for Risks & Charges
-
-
378.00
931.00
-
Other Liabilities
96.70
4,612.50
-
-
664.00
Total Liabilities
14,561.80
8,930.70
10,292.00
11,031.00
7,409.00
Common Equity (Total)
70,635.20
72,018.00
142,816.00
85,725.00
62,474.00
Total Shareholders' Equity
96.50
32,468.00
142,816.00
85,725.00
62,474.00
Total Equity
96.50
32,468.00
142,816.00
85,725.00
62,474.00
Liabilities & Shareholders' Equity
14,658.30
41,398.70
153,108.00
96,756.00
69,883.00
Preferred Stock (Carrying Value)
70,731.70
104,486.00
-
-
-

About Chiasma

View Profile
Address
460 Totten Pond Road
Waltham Massachusetts 02451
United States
Employees -
Website http://www.chiasmapharma.com
Updated 07/08/2019
Chiasma, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing and commercializing oral forms of therapies that are available by injection. Its products include octreotide capsules and clinical trials. The company's Transient Permeability Enhancer (TPE) technology platform, seeks to develop oral medications.